Dartmouth Health Continuing Education for Professionals Home, Medicine Grand Rounds - Gut Microbiome: Lessons from the REIMAGINE Study, Mark Pimentel, MD, FRCP(C), 2/28/2020 8:00:00 AM - 2/28/2023 9:00:00 AM, Dr. Pimentel discusses small bowel and stool microbiomes, how they differ and their connection to disease. The REIMAGINE Study is archiving small bowel bacteria prevalence and type, which may lead to targeted treatments for multiple chronic conditions. Small bowel bacterial overgrowth (SIBO) appears to be a key indicator not only in gastrointestinal disorders but also in autoimmune diseases. He discusses a variety of novel treatments for common conditions based on the specific study of the small intestine microbiome.
Presenter
Mark Pimentel, MD, FRCP(C)
Executive Director, Medically Associated Science and Technology (MAST) Program
Professor of Medicine, Geffen School of Medicine
Cedars-Sinai Medical Center
About our presenter: Dr. Pimentel completed his undergraduate work in microbiology and biochemistry at the University of Manitoba, Canada. He completed his medical degree and internal medicine residency at the University of Manitoba Health Sciences Center in Winnipeg, Manitoba, Canada.
Active in research, Dr. Pimentel has served as a principal investigator or co-investigator for numerous basic-science, translational and clinical studies in such areas as IBS, and the relationship between gut flora composition and human disease.
Learning Outcome(s)
Participants will be able to describe the growing importance of the microbiome in human disease, contrast the small bowel and stool microbiome and discuss how the small bowel microbiome relates to human disease.
Disclosure
In accordance with the disclosure policy of Dartmouth-Hitchcock/Geisel School of Medicine at Dartmouth as well as standards set forth by the Accreditation Council on Continuing Medical Education and the Nursing Continuing Education Council standards set forth by the American Nurses Credentialing Center Commission on Accreditation, continuing medical education and nursing education activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have been asked to disclose any financial relationship* they have to a commercial interest (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients). Such disclosure is not intended to suggest or condone bias in any presentation, but is elicited to provide participants with information that might be of potential importance to their evaluation of a given activity.
The following Activity Physician Director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for Gut Microbiome: Lessons from the REIMAGINE Study (Medicine Grand Rounds) have reported the following financial interest or relationship* with various companies/organizations. The Activity Director and Planning Committee member roles were resolved by altering the individual’s control over content about the products or services of the commercial interest by the Associate Dean for CME and the Department of Medicine Chair. The speaker conflict was resolved by validating the activity content through independent peer review by Kelly Kieffer, MD. All potential conflict(s) were resolved.
* Kelly Kieffer, MD ~ her spouse is a consultant for OcculoBio.
* Richard I. Rothstein, MD ~ has research support from Baranova (research grant to Dartmouth-Hitchcock Medical Center) and is on the Scientific Advisory Board for Allurion.
* Mark Pimentel, MD, FRCP(C) ~ has grant/research support from National Philanthropic Trust; is a consultant for Valeant, Commonwealth, NAIA, Synthetic Biologics; is a major stockholder of Synthetic Biologics, NAIA, Gemelli Biotech; is on the speaker bureau for Valeant; has other financial interest with Cedars Sinai.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this program report no financial interest or relationship* with any company(ies) or organizations whose product may be germane to the content of their presentations.
*A “financial interest or relationship" refers to an equity position, receipt of royalties, consultantship, funding by a research grant, receiving honoraria for educational services elsewhere, or to any other relationship to a company that provides sufficient reason for disclosure, in keeping with the spirit of the stated policy.
Presenter
Mark Pimentel, MD, FRCP(C)
Executive Director, Medically Associated Science and Technology (MAST) Program
Professor of Medicine, Geffen School of Medicine
Cedars-Sinai Medical Center
About our presenter: Dr. Pimentel completed his undergraduate work in microbiology and biochemistry at the University of Manitoba, Canada. He completed his medical degree and internal medicine residency at the University of Manitoba Health Sciences Center in Winnipeg, Manitoba, Canada.
Active in research, Dr. Pimentel has served as a principal investigator or co-investigator for numerous basic-science, translational and clinical studies in such areas as IBS, and the relationship between gut flora composition and human disease.
Learning Outcome(s)
Participants will be able to describe the growing importance of the microbiome in human disease, contrast the small bowel and stool microbiome and discuss how the small bowel microbiome relates to human disease.
Disclosure
In accordance with the disclosure policy of Dartmouth-Hitchcock/Geisel School of Medicine at Dartmouth as well as standards set forth by the Accreditation Council on Continuing Medical Education and the Nursing Continuing Education Council standards set forth by the American Nurses Credentialing Center Commission on Accreditation, continuing medical education and nursing education activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content have been asked to disclose any financial relationship* they have to a commercial interest (any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients). Such disclosure is not intended to suggest or condone bias in any presentation, but is elicited to provide participants with information that might be of potential importance to their evaluation of a given activity.
The following Activity Physician Director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for Gut Microbiome: Lessons from the REIMAGINE Study (Medicine Grand Rounds) have reported the following financial interest or relationship* with various companies/organizations. The Activity Director and Planning Committee member roles were resolved by altering the individual’s control over content about the products or services of the commercial interest by the Associate Dean for CME and the Department of Medicine Chair. The speaker conflict was resolved by validating the activity content through independent peer review by Kelly Kieffer, MD. All potential conflict(s) were resolved.
* Kelly Kieffer, MD ~ her spouse is a consultant for OcculoBio.
* Richard I. Rothstein, MD ~ has research support from Baranova (research grant to Dartmouth-Hitchcock Medical Center) and is on the Scientific Advisory Board for Allurion.
* Mark Pimentel, MD, FRCP(C) ~ has grant/research support from National Philanthropic Trust; is a consultant for Valeant, Commonwealth, NAIA, Synthetic Biologics; is a major stockholder of Synthetic Biologics, NAIA, Gemelli Biotech; is on the speaker bureau for Valeant; has other financial interest with Cedars Sinai.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this program report no financial interest or relationship* with any company(ies) or organizations whose product may be germane to the content of their presentations.
*A “financial interest or relationship" refers to an equity position, receipt of royalties, consultantship, funding by a research grant, receiving honoraria for educational services elsewhere, or to any other relationship to a company that provides sufficient reason for disclosure, in keeping with the spirit of the stated policy.
